Bio Pharma Dive
JUNE 3, 2021
Study results disclosed ahead of ASCO could make Lynparza a standard "adjuvant" treatment for people with an inherited form of breast cancer — as long as they know they have it.
World of DTC Marketing
JUNE 4, 2021
SUMMARY: The U.S. is one of the wealthiest countries in the world and accordingly has high obesity rates; one-third of the population has obesity plus another third is overweight. The cost of doing nothing is not an option. Yes, there are root causes for obesity that can’t be fixed quickly, but among the causes that we can try and change is our personal responsibility to live a healthier life.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
JUNE 2, 2021
Updated study results showed an overall response rate of 98% with a longer-term follow-up at a median of 18 months
pharmaphorum
JUNE 1, 2021
Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed. The Danish drugmaker has acquired exclusive rights outside Japan to Heartseed’s HS-001 therapy based on heart muscle cells (cardiomyocytes) derived from human stem cells, and is due to start the phase 1/2 LAPiS trial in Japan later this year.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
JUNE 3, 2021
The German drugmaker will add an experimental prostate cancer medicine to its pipeline through the deal, which reflects growing industry interest in the field.
World of DTC Marketing
JUNE 3, 2021
IN SHORT : Out-of-control health care spending exact an enormous and growing toll on Americans. The scale of the broken US health care system reveals itself in tragic ways. Fraud accounts for about $300 billion of annual US health care spending. Many employers no longer try to contain health care spending, but many more are fighting back. The Future of Health Care is Local, Open, and Independent.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Camargo
JUNE 4, 2021
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Approval of the Month: Non-Opioid for Post-Surgical Pain Gets FDA Nod. Heron Therapeutic received FDA approval for its bupivacaine/meloxicam extended-release solution product to treat post-operative pain after total knee replacement, bunionectomy, and groin hernia repair.
Bio Pharma Dive
JUNE 3, 2021
VenBio has previously invested in a range of treatment areas and technologies, including cell and gene editing companies like Precision Bio and Artiva.
World of DTC Marketing
MAY 30, 2021
SUMMARY: Amazon has set its sights on healthcare as it smells another profit opportunity. Google has signed an agreement with the Mayo clinic to help analyze data as they want a slice of healthcare dollars but what’s missing from these tech companies is “the human touch” that patients want. Via The New Republic “whether it believes its own rhetoric—or just smells another profit opportunity—the tech industry shows little sign of slowing its march into the world of commerci
Pharma Times
JUNE 2, 2021
Alkermes said that it is expecting to make Lybalvi available for patients in the fourth quarter of 2021
Pharma Mirror
JUNE 2, 2021
Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, announced today that it has acquired RIM Bio, a leading China-based manufacturer of single-use bioprocess bags and assemblies for biopharmaceutical manufacturing applications.
Bio Pharma Dive
JUNE 3, 2021
Results from the Phase 3 trial, which Novartis plans to use to ask for approval, help validate the pharma's bet on the therapy's original developer, Endocyte.
World of DTC Marketing
JUNE 1, 2021
SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. Kesselheim, a professor of medicine at Harvard Medical School via the Washington Post , says “the worst thing for people with Alzheimer’s would be to put out a product that doesn’t work.” For Biogen, the stakes are high as approval is likely to earn tens of millions, of to billions, in profits but is hope a reason to approve a drug over science?
Pharma Times
JUNE 4, 2021
The radioligand therapy was linked with a significant increase in progression-free survival and a clinically relevant increase in overall survival in patients with midgut neuroendocrine tumours
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Mirror
JUNE 2, 2021
Increasing instances of substandard, falsified and counterfeit medical products continue to pose a major challenge to the global healthcare system which is already suffering from the dire impact of COVID-19. To address this issue, ASPA and Messe Frankfurt India will unite leading experts from the pharmaceutical segment for a live panel discussion on 11 June 2021.
Bio Pharma Dive
JUNE 1, 2021
A deal with Kyowa Kirin gives Amgen rights to an experimental treatment aimed at an autoimmune target that has drawn interest from multiple drugmakers.
World of DTC Marketing
JUNE 2, 2021
SUMMARY: Doctors said they were dissatisfied were marketing emails (46%), telephone sales calls with sales reps (42%), and both webinars and websites (each at 39%) from pharma companies, according to Indegene. That should, however, not discourage the use of email to HCPs. If you follow some basic testing, email can be an effective tool for communicating information. 100 percent of U.S. pharma marketers use email marketing, and research shows that 73 percent of in-house marketers believe email m
Pharma Times
JUNE 4, 2021
Officials warned that early evidence suggests there may be an increased risk of hospitalisation for Delta compared to the Alpha (Kent) strain
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Mirror
JUNE 1, 2021
SIRIO Group’s global Nutra-Innovation Team is rapidly intensifying efforts to create new formulations in different delivery formats for mood and stress relief. The team’s focus follows a year of global lockdowns in which consumers faced significant challenges. This has led to a rise in demand for products that enhance personal health and wellness – mind and body – with formulations that boost mood and reduce stress in strong demand.
Bio Pharma Dive
JUNE 2, 2021
Royalty Pharma will effectively fund MorphoSys' acquisition of the cancer biotech through a separate agreement to buy MorphoSys' shares of royalties on several marketed and experimental medicines.
pharmaphorum
JUNE 3, 2021
The FDA has approved a digital device developed by Cognoa that can be used to diagnose autism spectrum disorder (ASD), just a few weeks after it was filed for approval. Cognoa says the artificial intelligence (AI) based device is the first to be authorised by the US regulator that can help doctors diagnose autism in primary care, and will be launched “in the coming months” At the moment, autism can be difficult to diagnose as there are no medical markers to confirm its presence.
Pharma Times
JUNE 3, 2021
IL-23 inhibitor helped patients achieve complete skin clearance and joint symptom improvement
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
NY Times
MAY 30, 2021
I tried everything to treat my depression. Ketamine is the one thing that worked.
Bio Pharma Dive
JUNE 4, 2021
Marc Dunoyer, the U.K. drugmaker's longtime finance chief, will move over to a strategy role and run Alexion as a rare disease unit within AstraZeneca.
pharmaphorum
JUNE 3, 2021
The UK government is talking to AstraZeneca about ordering additional doses of its COVID-19 vaccine that will target the beta variant of SARS-CoV-2 virus first identified in South Africa, according to Health Secretary Matt Hancock. The AZ/Oxford University vaccine and other shots from Pfizer/BioNTech and Moderna are known to have less efficacy against the beta variant – also known as B.1.351 – which is estimated to be around 50% more transmissible than earlier strains.
Pharma Times
JUNE 1, 2021
KHK4083 is an anti-OX40, fully human monoclonal antibody in development for the treatment of atopic dermatitis
BioSpace
MAY 31, 2021
Newly entrenched in a leadership role within one of the most complex therapeutic spaces, Tole discussed the complexities of being both a woman and a woman of color in the biotech industry.
Bio Pharma Dive
JUNE 1, 2021
Lybalvi is meant to be as effective as marketed antipsychotics but without the weight gain patients typically experience. Alkermes will introduce the drug into a competitive market, however.
BioPharma Reporter
MAY 31, 2021
OncoSTART sees 12 expert partners join forces to combine networks to promote entrepreneurial innovation to tackle cancer head on.
Pharma Times
JUNE 2, 2021
A WHO emergency use listing (EUL) is issued when a product meets international standards for safety, efficacy and manufacturing
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
356 
Let's personalize your content